Summary by Futu AI
On June 17, 2024, Novavax's President of R&D, Filip Dubovsky, completed a series of transactions involving the company's common stock. Dubovsky executed the sale of 13,904 shares at prices ranging from $14.46 to $14.54 per share, resulting in a total market value of $201,164.16. Prior to the sales, Dubovsky acquired the same number of shares through the exercise of derivative securities at prices between $6.09 and $6.97. Following these transactions, Dubovsky's direct holdings in Novavax common stock amounted to 66,613 shares.